Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) — Market Cap & Net Worth
Market Cap & Net Worth: Takeda Pharmaceutical Co Ltd ADR (TAK)
Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) has a market capitalization of $52.60 Billion ($52.60 Billion) as of April 27, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #498 globally and #246 in its home market, demonstrating a -6.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Takeda Pharmaceutical Co Ltd ADR's stock price $16.65 by its total outstanding shares 3159192822 (3.16 Billion).
Takeda Pharmaceutical Co Ltd ADR Market Cap History: 2015 to 2026
Takeda Pharmaceutical Co Ltd ADR's market capitalization history from 2015 to 2026. Data shows growth from $50.36 Billion to $52.54 Billion (1.04% CAGR).
Index Memberships
Takeda Pharmaceutical Co Ltd ADR is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Pharmaceutical
DRG
|
$3.12 Trillion | 1.69% | #10 of 24 |
Weight: Takeda Pharmaceutical Co Ltd ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Takeda Pharmaceutical Co Ltd ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Takeda Pharmaceutical Co Ltd ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Takeda Pharmaceutical Co Ltd ADR's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.46x
Takeda Pharmaceutical Co Ltd ADR's market cap is 0.46 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $43.98 Billion | $1.81 Trillion | $80.17 Billion | 0.02x | 0.55x |
| 2017 | $63.92 Billion | $1.73 Trillion | $114.94 Billion | 0.04x | 0.56x |
| 2018 | $40.17 Billion | $1.77 Trillion | $186.89 Billion | 0.02x | 0.21x |
| 2019 | $49.92 Billion | $2.10 Trillion | $109.13 Billion | 0.02x | 0.46x |
| 2020 | $48.28 Billion | $3.29 Trillion | $44.24 Billion | 0.01x | 1.09x |
| 2021 | $37.86 Billion | $3.20 Trillion | $376.00 Billion | 0.01x | 0.10x |
| 2022 | $45.36 Billion | $3.57 Trillion | $230.06 Billion | 0.01x | 0.20x |
| 2023 | $43.15 Billion | $4.03 Trillion | $317.02 Billion | 0.01x | 0.14x |
| 2024 | $41.83 Billion | $4.26 Trillion | $144.07 Billion | 0.01x | 0.29x |
| 2025 | $49.25 Billion | $4.58 Trillion | $107.93 Billion | 0.01x | 0.46x |
Competitor Companies of TAK by Market Capitalization
Companies near Takeda Pharmaceutical Co Ltd ADR in the global market cap rankings as of April 27, 2026.
Key companies related to Takeda Pharmaceutical Co Ltd ADR by market ranking:
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #505 globally with a market cap of $52.32 Billion USD ( CN¥357.54 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #516 globally with a market cap of $51.50 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #573 globally with a market cap of $45.88 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #621 globally with a market cap of $42.66 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #505 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $52.32 Billion | CN¥56.05 |
| #516 | Zoetis Inc | NYSE:ZTS | $51.50 Billion | $116.87 |
| #573 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $41.94 |
| #621 | Haleon plc | NYSE:HLN | $42.66 Billion | $9.58 |
Takeda Pharmaceutical Co Ltd ADR Historical Marketcap From 2015 to 2026
Between 2015 and today, Takeda Pharmaceutical Co Ltd ADR's market cap moved from $50.36 Billion to $ 52.54 Billion, with a yearly change of 1.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $52.54 Billion | +6.67% |
| 2025 | $49.25 Billion | +17.75% |
| 2024 | $41.83 Billion | -3.08% |
| 2023 | $43.15 Billion | -4.87% |
| 2022 | $45.36 Billion | +19.82% |
| 2021 | $37.86 Billion | -21.58% |
| 2020 | $48.28 Billion | -3.30% |
| 2019 | $49.92 Billion | +24.27% |
| 2018 | $40.17 Billion | -37.15% |
| 2017 | $63.92 Billion | +45.35% |
| 2016 | $43.98 Billion | -12.67% |
| 2015 | $50.36 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Takeda Pharmaceutical Co Ltd ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $52.60 Billion USD |
| MoneyControl | $52.60 Billion USD |
| MarketWatch | $52.60 Billion USD |
| marketcap.company | $52.60 Billion USD |
| Reuters | $52.60 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more